HOO-IMM PLUS-B
$65
The New Upgraded HOO-IMM PLUS-B an anti-viral treatment for acute and chronic HBV infected patients primarily focus on the viral entry inhibition also inhibit DNA Polymerase of HBV virus in combination with other multi target against HBV which could block re-infection and protect hepatocyte those are healthy liver cells opening a new natural therapeutic options without any means of side effects for HBV infected individuals. Hepatitis B Virus infection is the major health problem throughout the world affecting more than 350 million people who are carriers of this virus that can cause chronic hepatitis, liver cirrhosis and hepato cellular carcinoma.
5 STAR RATING ON GOOGLE & TRUSTPILOT.
Anti-HBV
The anti-HBV activity of HOO-IMM PLUS-B has been reported by many Ayush clinicians in India and pharmacist from Africa. HOO-IMM PLUS-B has been extensively clinically studied against HBV on the inhibition of HBsAg secretion and also the inhibition of Hepato carcinoma in HepG2 cell line. Clinically patients receiving HOO-IMM PLUS-B reported Target not detected in HBV DNA Quantitative.
Anti-Hepatocellular Carcinoma (HCC)
The HOO-IMM PLUS-B constitute molecule which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on molecule suggesting that it inhibits proliferation induces apoptosis, potentiate attenuate ROS.
But the poor systemic absorption of said molecule is major obstacle for its efficacy. Here we have a unique extraction procedure for said molecule which yields high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption.
Hepatoprotective
HOO-IMM PLUS-B prevents liver injury from viral hepatitis. HBV individuals receiving HOO-IMM PLUS-B treatment having normalized liver enzyme. The treatment prognosis reports normal level of the routine test of Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST). AST and SGPT is a blood test that checks for the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.
Biomarker or Test protocol involved in the anti-hbv treatment with HOO-IMM PLUS-B
- HBV Serological markers which include HBsAg Elisa.
- Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) & Aspartate Aminotransferase (AST) or SGOT.
- HBV DNA Quantification-Viral Load.
- Anti-HBs Test
Note: Quantification of HBV DNA reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment. This test is highly recommended in Chronic HBV- World Health Organization (WHO).
The New Upgraded HOO-IMM PLUS-B, a complete PCR proven Anti-HBV Treatment
The New Upgraded HOO-IMM Plus-B is a novel herbal formulation for the treatment of HBV infections manufactured by HOOTONE REMEDIES. It’s in the capsule formation consisting of 650 mg extract of 10 different plant species
Each 650 mg contains:-
| Ingredient Name | Botanical Name | Amount |
|---|---|---|
| Kalmegh Extract | Andrographis Paniculata | 70 mg |
| Afsantheen Extract | Artemisia Spp | 90 mg |
| Haldi Extract | Curcuma Longa | 50 mg |
| Mulethi Extract | Glycyrrhiza Glabra | 70 mg |
| Bhui Amlaki Extract | Phyllanthus Niruri | 90 mg |
| Masthagi | Pistacia Lentiscus | 70 mg |
| Anar Chal Extract | Punica Granatum | 60 mg |
| Oont Katara Extract | Milk Thistle | 70 mg |
| Harda Extract | Terminalia Chebula | 75 mg |
| Jisth Khusta | Zinc Calx | 5 mg |
The New Upgraded HOO-IMM PLUS-B polyherbal formulation consists of number active molecules of different plant species act on multiple targets against HBV.
Glycyrrhiza Glabra
Glycyrrhizin, a major component of a herb (licorice), has been widely used to treat chronic hepatitis B in Japan. This substance improves liver function with occasional complete recovery from hepatitis
Its effects on the secretion of hepatitis B surface antigen (HBsAg) were examined in vitro. Glycyrrhizin suppressed the secretion of HBsAg and accumulated it dose-dependently in PLC/PRF/5 cells.
Phyllanthus Niruri
An aqueous extract of the plant Phyllanthus niruri inhibits endogenous DNA polymerase of hepatitis B virus and binds to the surface antigen of hepatitis B virus in vitro.
Phyllanthus significantly reduced serum HBV DNA (a marker of efficacy) as well as HBeAg (a marker of viral replication).
A potential anti-HBV agent, ellagic acid, was isolated from the medicinal plant P. niruri, and its physicochemical properties were characterized.
Phyllanthus niruri (Bhumyamalaki) had ability to inhibit HBV polymerase to decrease episomal HBV DNA content by downregulating HBV messenger RNA transcription.
Terminalia Chebula
Studied and found that 90% of Terminalia chebula ethanolic extracts inhibited on HBs antigen binding assay and HBV DNA polymerase inhibition assay.
In silico analysis of potent compounds from Terminalia chebula proved to be effective against Hepatitis B virus.
In HBs antigen binding assay, the lyophilized ethanolic extracts of Terminalia chebula exhibited 60% of maximum inhibition whereas the aqueous extracts showed 55% of inhibition and the control lamivudine exhibited 60% of inhibition.
Cucurma Longa
Curcumin treatment led to time- and dose-dependent reductions in HBsAg and HBeAg expression and significant reductions in intracellular HBV DNA replication
Andrographis Panicula
Dehydroandrographolide and andrographolide, two natural diterpenoids isolated from Andrographis paniculata possessed activity against HBV DNA replication.
Anti-HBs Restoration
The New Upgraded HOO-IMM PLUS-B: Complete HBV Cure and Successful Recovery
Anti-HBs (Hepatitis B Surface antibody) is an antibody that the body naturally produces in response to the exposure against Hepatitis B Virus or vaccination against HBV. When the immune system recognizes the HBV surface antigen, it produces antibodies that bind to the antigen and neutralizes the virus. The antibodies (Anti-HBs) can also prevent future HBV infection.
Different trend of the person do not develop anti-HBs under the influence of Tenofovir drug. It has been found clinically the patient under the Tenofovir influences do not develop anti-HBs naturally for even after years of treatment.
Although with the low HBV DNA quant with Tenofovir treatment, the anti-HBs naturally developing antibodies have not been found against the absence of antigen since anti-HBs is an essential antibody to prevent body from future viral exposure or relapse. In such a case there is a loose end in successive HBV treatment.
On the contrary, HOO-IMM PLUS-B receiving patient develops anti-HBs for the existing viral exposure. The Anti-HBs response induced by HOO-IMM PLUS-B is much more detectable through commercially available anti-HBs test. For any drug-naive patient receiving therapy with HOO-IMM PLUS-B, there will be a noticeable rise in anti-HBs over time.
The patient under Tenofovir along with HOO-IMM PLUS-B in order to develop anti-HBs the patient has to withdraw Tenofovir and continue HOO-IMM PLUS-B alone for anti-HBs restoration.
Different bioactive compound of HOO-IMM PLUS-B targets different life activity of the virus apart from immune restoration to bring down the time duration for speedy recovery. It varies from patient to patient since the level of anti-HBs can vary depending on the severity and duration of the infection.
Also kindly find few reviews of the test results of patients undergone the anti-HBV treatment at https://curehbv.com/medical-records
